UK markets open in 1 hour 42 minutes

Centessa Pharmaceuticals Limited (CNTA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
12.01-0.71 (-5.58%)
At close: 04:00PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.14B
Enterprise value 1.09B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-41.52%
S&P500 52-week change 322.59%
52-week high 326.90
52-week low 310.50
50-day moving average 314.47
200-day moving average 318.93

Share statistics

Avg vol (3-month) 3220.2k
Avg vol (10-day) 3254.64k
Shares outstanding 589.9M
Implied shares outstanding 6N/A
Float 839.26M
% held by insiders 11.92%
% held by institutions 163.38%
Shares short (14 Nov 2021) 41.97M
Short ratio (14 Nov 2021) 410.68
Short % of float (14 Nov 2021) 4N/A
Short % of shares outstanding (14 Nov 2021) 42.19%
Shares short (prior month 14 Oct 2021) 41.61M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 3N/A
Trailing annual dividend yield 3N/A
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2020
Most-recent quarter (mrq)29 Sept 2021

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)N/A
Return on equity (ttm)N/A

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA N/A
Net income avi to common (ttm)-331.81M
Diluted EPS (ttm)-3.69
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)578.81M
Total cash per share (mrq)6.44
Total debt (mrq)N/A
Total debt/equity (mrq)N/A
Current ratio (mrq)20.99
Book value per share (mrq)6.11

Cash flow statement

Operating cash flow (ttm)-72.32M
Levered free cash flow (ttm)N/A